Analysis of HIV-1 clinical trials: Statistical magic?

Lancet

Volumn 353, Issue 9169, 1999, Pages 2061-2064

  Cooper, D ^a   Clumeck, N ^a   Montaner, J ^a   Harrigan, R ^a   Gerstoft, J ^a   Rozenbaum, W ^a   Goebel, F D ^a   Reiss, P ^a   Lange, J ^a   Vella, S ^a   Gatell Artigas, J M ^a   Gazzard, B ^a   Hill, A M ^a   DeMasi, R ^a   Athisegaran, R ^a   Moore, S ^a   Maguire, M ^a   Gartland, M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; VIRUS RNA; ZIDOVUDINE;

CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL ANALYSIS; VIREMIA;

EID: 0033549338     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10391-4     Document Type: Note

References (21)

1. Mellors J.W., Munoz A., Giorgi J.V.et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 126:1997;946-954.
2. Gazzard B., Moyle G.and 1998 revision to the British Association guidelines for antiretroviral treatment for HIV infection. Lancet. 352:1998;314-316.
3. Carpenter C.J., Fischl M.A., Hammer S.M.et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS society - USA panel. JAMA. 280:1998;78-86.
4. Yu, G., Clendennin, C., Quart, B., et al. Viral load determinations during treatment with Viracept combination treatment as predictor of response and guidance for treatment choice strategy. 12th World AIDS Conference, Geneva, June 18 to July 3, 1998: 12300 (abstr).
5. Raboud J., Montaner J., Conway B.et al. Suppression of viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS. 12:1998;1619-1624.
6. Kahn, J., Mayers, D., Riddler, S., et al. Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP 26) in combination with indinavir (IDV): suppression to "<1 copy/mL" (OD=background) by Amplicator as a predictor of virologic treatment response (DMP-266-03, cohort IV). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February, 1998: 692 (abstr).
7. Ionnadis J., Bassett R., Hughes M.et al. Predictors and impact of patients lost to follow-up in a long-term randomised trial of immediate versus deferred antiretroviral treatment. J Aquir Immune Defic Syndr Hum Retrovirol. 16:1997;22-30.
8. Phillips, A.N., McLean, A., Loveday, C., et al. HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis. International Meeting on HIV Population Dynamics, Variation and Drug Resistance. Edinburgh, March, 1997.
9. Staszewski, S., Morales-Ramirez, J., Tashima, K., et al. A phase II, multicentre, randomised, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (lamivudine), versus IDV + ZDV + lamivudine at 24 weeks [DMP266-006]. 12th World AIDS Conference, Geneva, June 28 to July 3, 1998: 22336 (abstr).
10. Staszewski S., DeMasi R., Hill A., Dawson D. HIV-1 RNA, CD4 count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS. 12:1998;1-6.
11. Goebel, F., on behalf of the AVANTI study group. AVANTI-2. A randomised, double-blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC versus AZT/3TC/indinavir in anti-retroviral naï patients. Sixth European conference on clinical aspects and treatment of HIV-infection. Hamburg, October, 1997: 211 (abstr).
12. Clumeck, N., for the AVANTI study group. AVANTI-3: a randomised double-blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC versus AZT/3TC/nelfinavir in antiretroviral naï patients. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, February, 1998: 8 (abstr).
13. Gullick R.M., Mellors J.W., Havlir D.et al. Simultaneous vs sequential initation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. 100 week follow-up. JAMA. 280:1998;35-41.
14. Gullick, R., Squires, K., Powderly, W., et al. An open-label, randomised, comparative study of stavudine + lamivudine + indinavir versus zidovudine + lamivudine + indinavir in treatment naï HIV-1 infected subjects. 12th World AIDS Conference, Geneva, June 18 to July 3, 1998: 12223 (abstr).
15. Eron, J., Peterson, D., Murphy, R., et al. An open-label, randomised, comparative study of stavudine + didanosine + indinavir versus zidovudine + lamivudine + indinavir in treatment naï HIV-infected subjects. 12th World AIDS Conference, Geneva, June 28 to July 3, 1998: 12225 (abstr).
16. Moyle G., on behalf of the SPICE Study Team. Study of protease inhibitor (PI) combination in Europe (SPICE): soft galatin capsule (SQV-SGC) plus nelfinavir (NFV) in HIV-infected individuals. 12th World AIDS Conference, Geneva, June 18 to July 3 1998: 12222 (abstr).
17. Kirk O., Katzenstein T., Gerstoft J.et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomised trial. AIDS. 13:1999;F9-F16.
18. Mitsayasu T., Skolnik P.R., Cohen S.R.et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naï patients. AIDS. 12:1998;F103-F109.
19. Haas, D.W., Seekins, D., Cooper, R., et al. A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efarirenz (EFV, SUSTIVAe, DMP266) in combination with open-label zidovudine (ZDV) with lamivudine (lamivudine) at 36 weeks [DMP266-005]. 12th World AIDS Conference, Geneva, June 18 to July 3, 1998: 22334 (abstr).
20. Montaner J.S.G., Reiss P., Cooper D.et al. A randomised, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected persons - the INCAS trial. JAMA. 279:1998;930-937.
21. Fischl, M., Greenberg, S., Clumeck, N., et al. Safety and activity of abacavir (ABC, 1592) with lamivudine/ZDV in antiretroviral naï subjects. 12th World AIDS Conference, Geneva, June 28 to July 3, 1998: 12230 (abstr).